‘This could be a large market’: Novo Holdings-backed Claris secures $118M for corneal disease drug July 27, 2026Posted inBiotechnology A new biotech has come into view with a $118 million series B and a vision for making the front of the eye front-of-mind. Post navigation Previous Post Multidisciplinary Neurohemodynamics Team Improves Echocardiography-Guided Care for Neonatal AVMsNext PostFirst patient enrolled in Phase 3 trial of mocertatug rezetecan for platinum-resistant ovarian cancer
